Mahmoud Obeidat

Dr. Mahmoud Obeidat

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2023 in eClinicalMedicine
Verified
Journal Article
Open access
KBKinga Anna Budai
Kinga Anna Budai
ÁTÁgnes Eszter Tímár
Ágnes Eszter Tímár
Mahmoud ObeidatMahmoud Obeidat
Mahmoud Obeidat
VMVanda Máté
Vanda Máté
RNRita Nagy
Rita Nagy
CLCsaba Lódi
Csaba Lódi
Paediatric patients are often exposed to subtherapeutic levels or treatment failure of β-lactams, and prolonged infusion may be beneficial. We aimed to investigate the efficacy and safety of extended infusion (EI; defined as ≥3 h) or continuous infusion vs. short, intermittent infusion (SI; defined as ≤60 min) of β-lactams in patients 21 years were excluded. Odds ratios (OR) and median differences with 95% confidence intervals (CI) were calculated using a random-effects model. Risk of bias (ROB) was assessed using ROB2 and ROBINS-I tools. The protocol was registered with PROSPERO, CRD42022375397. In total, 19,980 articles were screened, out of which 19 studies (4195 patients) were included in the meta-analysis. EI administration was associated with a significantly lower all-cause mortality in both RCTs and non-RCTs [OR 0.74; CI 0.55–0.99; I2 = 0%; CI 0–58%]. Early microbiological eradication was higher with EI [OR 3.18; CI 2.24–4.51; I2 = 0%; CI 0–90%], but the clinical cure did not differ significantly between the two groups [OR 1.20; CI 0.17–8.71; I2 = 79%; CI 32–93%]. Achieving the optimal plasma level (50–100% fT > MIC) appeared favourable in the EI group compared to the SI. No significant differences were observed in the adverse events. The overall ROB was high because of the small sample sizes and clinically heterogeneous populations. Our findings suggest that extended infusion of β-lactams was associated with lower mortality and increased microbiological eradication and was considered safe compared to short-term infusion. None.

20 February 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RKRenáta Kiss-Miki
Renáta Kiss-Miki
Mahmoud ObeidatMahmoud Obeidat
Mahmoud Obeidat
VMVanda Máté
Vanda Máté
BTBrigitta Teutsch
Brigitta Teutsch
GAGergely Agócs
Gergely Agócs
Miklós GaramiMiklós Garami
Miklós Garami
Background: With the introduction of new therapy modalities and the resulting increase in survival rates, childhood brain cancers have become a focal point of research in pediatric oncology. In current protocols, besides surgical resection and chemotherapy, radiotherapy is required to ensure optimal survival. Our aim was to determine which of the two major irradiation options, proton (PT) or photon (XRT), was the least harmful yet effective for children with brain tumors. Methods: The protocol was registered on PROSPERO in advance (CRD42022374443). A systematic search was performed in four databases (MEDLINE via (PubMed), Embase, Cochrane Library, and Scopus) on 23 April 2024. Odd ratios (OR) and mean differences (MD) with 95% confidence intervals (CI) were calculated using a random-effects model. Survival and six major types of side effects were assessed based on data in the articles and reported using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Heterogeneity was assessed using Higgins and Thompson’s I2 statistics. Results: Altogether, 5848 articles were screened, of which 33 were eligible for data extraction. The 5-year overall survival results showed statistically no significant difference between the two radiotherapy modalities (OR = 0.80, 95% CI: 0.51–1.23, p = 0.22, I2 = 0%). In terms of toxicity rates, an advantage was found for PT, particularly in terms of chronic endocrine side effects (hypothyroidism OR: 0.22, 95% CI: 0.10–0428, p = 0.002, I2 = 68%), neurocognitive decline (global IQ level MD: 13.06, 95% CI: 4.97–21.15, p = 0.009, I2 = 68%). As for hematological, acute side effects, neurological changes and ophthalmologic disorders PT can be beneficial for survivors in terms of reducing them. Conclusions: In comparison with XRT, PT can reduce most side effects, without significantly decreasing the survival rate. There is considerable clinical relevance in the findings, even not all of them are statistically significant, which may facilitate the development of protocols regarding the usage of radiotherapy methods, and may encourage the establishment of more proton centers, where more studies can be done.

5 October 2025 in Gut Microbes
Verified
Journal Article
Open access
DIDiana-Elena Iov
Diana-Elena Iov
Mahmoud ObeidatMahmoud Obeidat
Mahmoud Obeidat
SVSzilárd Váncsa
Szilárd Váncsa
SKSarolta Beáta Kávási
Sarolta Beáta Kávási
LFLászló Földvári-Nagy
László Földvári-Nagy
BEBalint Eross
Balint Eross
Observational studies reported conflicting results regarding the association between proton pump inhibitors (PPIs) and intestinal dysbiosis. We assessed the risk of enteric infections, including Clostridioides difficile infection (CDI), and small intestinal bacterial overgrowth (SIBO) among PPI users compared to non-users in randomized controlled trials (RCTs). A systematic search was conducted on April 15th, 2025 (CRD42023403322). Eligible RCTs compared adults treated with PPIs versusplacebo or alternative therapies. Risk ratios (RR) with corresponding 95% confidence interval (CI) were calculated using random effects models. Eight RCTs with 29,880 participants reported CDI rates. No significant difference was observed between PPI users and non-users (RR = 1.19, 95% CI: 0.75; 1.89). Four RCTs totaling 27,254 participants compared PPIs to H2-receptor blockers, showing no significant difference in CDI risk (RR = 0.72, 95% CI: 0.49; 1.07). Similarly, three RCTs (1,645 participants) comparing PPIs with potassium-competitive acid blockers found no significant difference (RR = 1.23, 95% CI: 0.43; 3.55). The qualitative synthesis found that other enteric infections and SIBO may be more common in PPI users. Data from RCTs suggest that PPIs do not seem to increase the risk of CDI compared to placebo and other acid-suppressive medications.

21 November 2024 in eClinicalMedicine
Verified
Journal Article
Open access
PVPetra Varga
Petra Varga
Mahmoud ObeidatMahmoud Obeidat
Mahmoud Obeidat
VMVanda Máté
Vanda Máté
TKTamás Kói
Tamás Kói
SKSzilvia Kiss-Dala
Szilvia Kiss-Dala
ETEszter Tuboly
Eszter Tuboly
Current paediatric cancer care requires innovative approaches to predict prognosis that facilitates personalised stratification, yet studies on the performance, composition and limitations of contemporary prognostic models are lacking. We aimed to compare the accuracy of traditional and advanced prognostic models. A systematic search for this systematic review and meta-analysis (CRTN42022370251) was conducted in PubMed, Embase, Scopus, and the Cochrane Library databases on 28 June 2024. Studies on the accuracy of prognostic markers or models used in paediatric haematological malignancies, central nervous system (CNS), or non-CNS solid tumours (NCNSST) were included. Three model categories were defined using: 1-clinical parameters, 2-genomic-transcriptomic data, and 3-artificial intelligence (AI). Primary outcomes were area under the receiver operating characteristic curve with a 95% confidence interval (CI) for various overall survival intervals and event-free survival. Two independent groups performed selection and data extraction. We used data published by the authors and publicly available databases. Of 12,982 studies, 358 were included in the meta-analysis and 27 in the systematic review, with limited data on AI-approaches. Most data were reported on NCNSST at 5-year OS, where a statistically significant difference was observed between Category-1 (0.75 CI: 0.72–0.79) and Category-2 (0.85 CI: 0.82–0.88) (p < 0.001), but not between Categories-2 and -3 (p = 0.2834) (0.82 CI: 0.77–0.88). Internal validation studies showed significantly better performance compared to those using external validation, highlighting the high risk of bias (ROB) inherent in internal validation. High ROB was most commonly experienced in the outcomes and statistical analysis domains, assessed using PROBAST and QUIPS. It is advisable to introduce Category-2 and -3 models in a clinical setting, especially for NCNSST prognostic for aiding risk-stratification. Although AI-supported predictions in paediatric oncology are at an early stage of development, it is imperative to further explore their potential. This requires structured data collection and ethical sharing from paediatric oncology patients in sufficient quantity and quality. None.

3 March 2026 in Pancreatology
Verified
Journal Article
Open access
OEOrsolya Eperjesi
Orsolya Eperjesi
MBMaria Bucur
Maria Bucur
ARAnett Rancz
Anett Rancz
ÁZÁdám Zolcsák
Ádám Zolcsák
MEMarie Anne Engh
Marie Anne Engh
SBStefania Bunduc
Stefania Bunduc
Pancreatic exocrine insufficiency (PEI) may develop after acute pancreatitis (AP). The incidence and predisposing factors are not well described, nor is optimal pancreatic enzyme replacement (PERT) in this setting. We aimed to investigate the proportion, risk factors, and effect of PERT in patients with PEI after AP. The study protocol was registered on PROSPERO (CRD42024516403). We systematically searched three databases (PubMed, EMBASE, and CENTRAL) on November 08, 2025. We included studies reporting on risk factors and PERT efficacy in PEI associated with AP. Pooled proportion and odds ratios (OR) with the 95% confidence intervals (CI) were calculated using a random-effects model. We identified 64 eligible articles. PEI occurred in 22% (CI:17-27%) of the 24111 analyzed AP patients. The rate was high at discharge at 48% (CI: 19-79%) but decreased and stabilized at 26% (CI: 17-39%) after the 1st year of follow-up. The rates of PEI were 10% (CI: 5-20%), 24% (CI:13-40%), and 31% (CI: 18-47%) after mild, moderately severe, and severe AP, respectively. The proportion of severe PEI reached 21% (CI: 13-31%) overall, and even following mild AP, severe PEI was observed in 10% (CI:4-22%) of cases. The odds were significantly higher for alcoholic (vs. biliary) AP (OR = 1.89, CI: 1.06-3.37) cases. Necrosis did not significantly increase the risk of PEI (OR = 2.12, CI: 0.54-8.28), but necrosectomy did (OR = 3.09, CI:1.79-5.31). PEI affects one in five AP patients in the long term. Alcoholic AP and necrosectomy are risk factors for AP-induced PEI. PEI can develop even after mild AP.

17 July 2025 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
ARAnett Rancz
Anett Rancz
BTBrigitta Teutsch
Brigitta Teutsch
Mahmoud ObeidatMahmoud Obeidat
Mahmoud Obeidat
AWAnna Walter
Anna Walter
GWGergő Weidinger
Gergő Weidinger
EMEmese Mihály
Emese Mihály
Background: Microscopic colitis (MC) is still an underdiagnosed disease due to its primarily histological appearance. We aimed to address the scarcity and inconsistency of data on MC risk factors.Methods: Our protocol was prospectively registered in PROSPERO (CRD42022286624). We systematically searched PubMed, Embase, and Cochrane from inception to January 6, 2025. Cohort, case–control, and cross‐sectional studies were included. Controls were distinguished with or without a histopathological examination. We used the random‐effect model to calculate pooled odds ratios (ORs) with 95% confidence intervals (CIs).Results: The systematic search yielded 6493 articles, of which 45 were meta‐analyzed. We found increased odds for MC in the case of nonsteroidal anti‐inflammatory drug (NSAID) and statin use compared to histological (OR = 2.57, CI: 1.45–4.53; OR = 2.15, CI: 1.14–4.05) and random (OR = 2.56, CI: 1.13–5.79; OR = 1.84, CI: 0.58–5.80) controls. Our results did not show an association between proton pump inhibitors (PPIs) and MC, compared to histological controls (OR = 1.81, CI: 0.75–4.35), except in the case of random controls (OR = 4.31, CI: 1.66–11.20). Neither current (OR = 1.35, CI: 0.88–2.06) nor previous smoking (OR = 1.26, CI: 0.67–2.39) increased the odds of MC compared to histological controls. In contrast, the odds doubled for current smoking and slightly changed for past smoking when MC patients were compared to random controls (OR = 2.40, CI: 1.64–3.50; OR = 1.11, CI: 0.93–1.31).Conclusions: NSAID and statin treatment were associated with an increased risk for MC compared to histological controls. PPIs and smoking showed only an association with MC when random controls were used.